Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T cells, supports the function of inflammatory T cells, exacerbating skin dysfunction. Researchers from Astria Therapeutics Inc. presented the preclinical characterization of STAR-0310, a humanized monoclonal IgG1 antibody targeting OX40.
The signaling of TNF receptor (TNFR) superfamily member 4 (OX40) and its ligand (OX40L) plays a crucial role in the development of immunological and inflammatory disorders due to triggering a subset of T-cell responses.
Inhibition of OX40 is known to induce and maintain responses in moderate to severe atopic dermatitis (AD). Astria Therapeutics Inc. and Ichnos Sciences Inc. are developing STAR-0310, a YTE-modified (M252Y/S254T/T256E) monoclonal antibody targeting OX40.
